TY - JOUR
T1 - The Tumor-Endothelium Interaction in Pioneering Studies and the Revisited Concept on the Angiogenesis Process During Tumor Progression and Metastasis
AU - Rizzi, Manuela
AU - Gallazzi, Matteo
AU - Tosetti, Francesca
AU - Mortara, Lorenzo
N1 - Funding Information:
This work was supported by University of Insub-ria intramural grants Fondi di Ateneo per la Ricerca FAR 2018 and FAR 2019 to LM. MG is a participant to Ph.D. course in Life Sciences and Biotechnology, University of Insubria, and a recipient of a research grant from Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN), Grant 2017NTK4HY (to Douglas M. Noonan).
Publisher Copyright:
© Mattioli 1885.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - The growth of solid tumors and their dissemination require the continuous formation of new capillary blood vessels. However, the association of uncontrolled growth of tumors and angiogenesis, i.e. the mechanism that allows the formation of new blood vessels starting from pre-existing vessels, dates back to 1971, in relation of Judah Folkman's works. Since then, his group and other researchers added new key results confirming the important role played by angiogenesis in tumor growth and metastasis, and multiple efforts have been made to exploit this knowledge in developing innovative anti-cancer therapies. In this article, we discuss seminal works regarding molecular mechanisms involved in aberrant tumor angiogenesis, biology of endothelial cells within extracellular matrix, function of diverse pro- and anti-angiogenic factors, roles of metalloproteinases and protumor effects played by stromal and immune cells in the tumor microenvironment. Interestingly, growing evidences indicate a key role played by inflammatory and stromal cells in both tumor development and progression. The present article also aim to provide up-to-date information concerning new therapeutic concepts involving tumor vessels normalization and anti-angiogenic agents, among which inhibitors of metalloproteinases and of the main angiogenic factor, vascular endothelial growth factor (VEGF) or its receptors, and the combination of them with immune checkpoint blockade, that seem to be the most promising ones at present.
AB - The growth of solid tumors and their dissemination require the continuous formation of new capillary blood vessels. However, the association of uncontrolled growth of tumors and angiogenesis, i.e. the mechanism that allows the formation of new blood vessels starting from pre-existing vessels, dates back to 1971, in relation of Judah Folkman's works. Since then, his group and other researchers added new key results confirming the important role played by angiogenesis in tumor growth and metastasis, and multiple efforts have been made to exploit this knowledge in developing innovative anti-cancer therapies. In this article, we discuss seminal works regarding molecular mechanisms involved in aberrant tumor angiogenesis, biology of endothelial cells within extracellular matrix, function of diverse pro- and anti-angiogenic factors, roles of metalloproteinases and protumor effects played by stromal and immune cells in the tumor microenvironment. Interestingly, growing evidences indicate a key role played by inflammatory and stromal cells in both tumor development and progression. The present article also aim to provide up-to-date information concerning new therapeutic concepts involving tumor vessels normalization and anti-angiogenic agents, among which inhibitors of metalloproteinases and of the main angiogenic factor, vascular endothelial growth factor (VEGF) or its receptors, and the combination of them with immune checkpoint blockade, that seem to be the most promising ones at present.
KW - anti-angiogenic agents
KW - biology of endothelial cells
KW - tumor angiogenesis
KW - tumor vessels normalization
UR - http://www.scopus.com/inward/record.url?scp=85099231191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099231191&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85099231191
SN - 2532-2370
VL - 10
SP - 20
EP - 28
JO - Medicina Historica
JF - Medicina Historica
IS - 2
ER -